1. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?. Issue 4 (3rd January 2020) Authors: Inzucchi, Silvio E.; Fitchett, David; Jurišić‐Eržen, Dubravka; Woo, Vincent; Hantel, Stefan; Janista, Christina; Kaspers, Stefan; George, Jyothis T.; Zinman, Bernard Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 4(2020) Page Start: 631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®. (December 2020) Authors: Langslet, Gisle; Zinman, Bernard; Wanner, Christoph; Hantel, Stefan; Espadero, Rosa-Maria; Fitchett, David; Johansen, Odd Erik Journal: Diabetes & vascular disease research Issue: Volume 17:Number 6(2020:Nov.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. (January 2015) Authors: Geiger, Mary Jane; Mehta, Cyrus; Turner, J. Rick; Arbet-Engels, Christophe; Hantel, Stefan; Hirshberg, Boaz; Koglin, Joerg; Mendzelevski, Boaz; Sager, Philip T.; Shapiro, Deborah; Stewart, Murray; Todaro, Thomas G.; Gaydos, Brenda Journal: Therapeutic innovation & regulatory science Issue: Volume 49:Number 1(2015:Jan.) Page Start: 50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Issue 12 (December 2020) Authors: McGuire, Darren K; Zinman, Bernard; Inzucchi, Silvio E; Wanner, Christoph; Fitchett, David; Anker, Stefan D; Pocock, Stuart; Kaspers, Stefan; George, Jyothis T; von Eynatten, Maximilian; Johansen, Odd Erik; Jamal, Waheed; Mattheus, Michaela; Elsasser, Ulrich; Hantel, Stefan; Lund, Søren S Journal: Lancet Issue: Volume 8:Issue 12(2020) Page Start: 949 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. (28th August 2017) Authors: Fitchett, David; Butler, Javed; van de Borne, Philippe; Zinman, Bernard; Lachin, John M; Wanner, Christoph; Woerle, Hans J; Hantel, Stefan; George, Jyothis T; Johansen, Odd Erik; Inzucchi, Silvio E Journal: European heart journal Issue: Volume 39:Number 5(2018) Page Start: 363 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. (3rd October 2019) Authors: Monteiro, Pedro; Bergenstal, Richard M; Toural, Elvira; Inzucchi, Silvio E; Zinman, Bernard; Hantel, Stefan; Kiš, Sanja Giljanovic; Kaspers, Stefan; George, Jyothis T; Fitchett, David Journal: Age and ageing Issue: Volume 48:Number 6(2019) Page Start: 859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial. Issue 3 (7th January 2019) Authors: Kadowaki, Takashi; Nangaku, Masaomi; Hantel, Stefan; Okamura, Tomoo; von Eynatten, Maximilian; Wanner, Christoph; Koitka‐Weber, Audrey Journal: Journal of diabetes investigation Issue: Volume 10:Issue 3(2019) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LBPS 02-47 CARDIOVASCULAR OUTCOMES ACCORDING TO LDL CHOLESTEROL LEVELS IN EMPA-REG OUTCOME. (September 2016) Authors: Lee, Dae Wook; Langslet, Gisle; Zinman, Bernard; Wanner, Christoph; Hantel, Stefan; Espadero, Rosa-Maria; Johansen, Odd Erik; Fitchett, David Journal: Journal of hypertension Issue: Volume 34:(2016) Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME. (September 2016) Authors: Lee, Dae Wook; Monteiro, Pedro; Clark, Douglas; Hantel, Stefan; Woerle, Hans J.; Inzucchi, Silvio E.; Fitchett, David Journal: Journal of hypertension Issue: Volume 34:(2016) Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial. (4th October 2021) Authors: Fitchett, David; Inzucchi, Silvio E.; Zinman, Bernard; Wanner, Christoph; Schumacher, Martin; Schmoor, Claudia; Ohneberg, Kristin; Ofstad, Anne Pernille; Salsali, Afshin; George, Jyothis T.; Hantel, Stefan; Bluhmki, Erich; Lachin, John M.; Zannad, Faiez Journal: ESC heart failure Issue: Volume 8:Number 6(2021) Page Start: 4517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗